MedTrace Logo

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

NCT05566002 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-04-08

No results posted yet for this study

Summary

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

Conditions

Interventions

DIAGNOSTIC_TEST

Right heart catheterization

RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).

Sponsors & Collaborators

  • Chinese Pulmonary Vascular Disease Research Group

    lead OTHER

Principal Investigators

  • Zhihong Liu, MD, PhD · Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566002 on ClinicalTrials.gov